Axsome Therapeutics (AXSM) Payables (2022 - 2025)
Historic Payables for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $225.6 million.
- Axsome Therapeutics' Payables rose 8467.78% to $225.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $225.6 million, marking a year-over-year increase of 8467.78%. This contributed to the annual value of $148.0 million for FY2024, which is 6351.97% up from last year.
- Per Axsome Therapeutics' latest filing, its Payables stood at $225.6 million for Q3 2025, which was up 8467.78% from $170.9 million recorded in Q2 2025.
- In the past 5 years, Axsome Therapeutics' Payables ranged from a high of $225.6 million in Q3 2025 and a low of $12.6 million during Q1 2022
- Its 4-year average for Payables is $95.5 million, with a median of $82.7 million in 2024.
- Per our database at Business Quant, Axsome Therapeutics' Payables skyrocketed by 36664.13% in 2023 and then soared by 4073.57% in 2024.
- Axsome Therapeutics' Payables (Quarter) stood at $51.6 million in 2022, then soared by 75.28% to $90.5 million in 2023, then soared by 63.52% to $148.0 million in 2024, then skyrocketed by 52.47% to $225.6 million in 2025.
- Its last three reported values are $225.6 million in Q3 2025, $170.9 million for Q2 2025, and $149.2 million during Q1 2025.